New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
12:06 EDTBBEP, SFLY, CHRW, BPI, NVSHigh option volume stocks: BBEP SFLY CHRW BPI NVS
News For BBEP;SFLY;CHRW;BPI;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
October 21, 2014
11:30 EDTBBEPOptions with decreasing implied volatility
Subscribe for More Information
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
08:33 EDTBBEPBreitBurn Energy provides update on QR Energy acquisition
Breitburn Energy Partners LP (BBEP) announced that the Registration Statement on Form S-4 concerning Breitburn’s acquisition of QR Energy, LP (QRE) was declared effective by the SEC on October 17, 2014. QR Energy will hold a special meeting of its unitholders on November 18, 2014, at 2:00 p.m., Central Time, at the Four Seasons Hotel, 1300 Lamar Street, Houston, Texas. QR Energy unitholders of record at the close of business on October 13, 2014, will be entitled to receive notice of the special meeting and to vote at the special meeting. The transaction, which was announced on July 24, 2014, was unanimously approved by the boards of directors of Breitburn and QR Energy. In addition, certain QR Energy unitholders owning approximately 37% of the votes of the outstanding QR Energy units have agreed to vote in favor of the transaction. Completion of the transaction is subject to the approval of QR Energy unitholders and customary closing conditions. The transaction is expected to close in late November.
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
October 17, 2014
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
October 15, 2014
17:03 EDTNVSNovartis announces CTL019 data demonstrating efficacy in certain ALL patients
Novartis and the University of Pennsylvania's Perelman School of Medicine announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine, or NEJM, evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia, or r/r ALL. The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor, or CAR, therapy CTL019. Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA. Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%.
07:07 EDTBPIFor profit education positive catalysts outweigh negative, says Wells Fargo
Wells Fargo expects for-profit education stocks to benefit from improved hiring trends and a sale by Corinthian of its assets that, according t othe firm ,would set a valuation floor for the sector. The firm continues to believe that the final gainful employment rule will be neutral to positive for the group. Wells favors the option value on the long side for the sector. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
06:52 EDTCHRWC.H. Robinson upgraded to Neutral from Underperform at Macquarie
Macquarie upgraded C.H. Robinson to Neutral based on improving competitive conditions and expectations for better than expected net revenue margins. Price target is $64.50.
October 14, 2014
11:23 EDTNVSBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
09:21 EDTSFLYOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTSFLYShutterfly volatility elevated into Silver Lake said to shelve effort to buy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use